Effects of Uric Acid Levels on Outcome in Severe Ischemic Stroke Patients Treated with Intravenous Recombinant Tissue Plasminogen Activator

被引:20
|
作者
Lee, Sang-Hwa [1 ]
Heo, Sung Hyuk [1 ]
Kim, Jun-Hyun [1 ]
Lee, Dokyung [1 ]
Lee, Ji Sung [2 ]
Kim, Young Seo [3 ]
Kim, Hyun Young [3 ]
Koh, Seong-Ho [3 ]
Chang, Dae-Il [1 ]
机构
[1] Kyung Hee Univ, Coll Med, Dept Neurol, Seoul, South Korea
[2] Korea Univ, Dept Biostat, Seoul, South Korea
[3] Hanyang Univ, Dept Neurol, Coll Med, Seoul 133791, South Korea
关键词
Uric acid; Thrombolysis; Neuroprotective antioxidant; Functional outcome; PLACEBO-CONTROLLED TRIAL; CORONARY-HEART-DISEASE; THROMBOLYTIC THERAPY; BRAIN ISCHEMIA; DOUBLE-BLIND; RISK; NEUROPROTECTION; HYPERURICEMIA; INJURY; MODEL;
D O I
10.1159/000355020
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Uric acid (UA) has been known to be a neuroprotective antioxidant because of its free radical scavenger activity. We studied the influence of UA in patients with acute ischemic stroke after thrombolytic therapy. Two hundred eighteen consecutive patients treated with intravenous thrombolysis were included in this analysis. We analyzed the relationship between serum UA levels obtained at the emergency department and clinical outcomes. Early improvement and excellent functional outcomes were measured using the National Institutes of Health Stroke Scale (NIHSS) 24 h after onset and the modified Rankin scale after 3 months. There was no significant relationship between serum UA levels and early improvement or excellent functional outcome in the total patients (p = 0.583 and p = 0.082, respectively). However, in patients with severe baseline stroke deficits (NIHSS score >= 15), higher-tertile UA levels were significantly associated with excellent functional outcomes (p = 0.003). Excellent functional outcomes in patients with severe baseline disability might have a significant association with serum UA levels particularly in men but not in women (p = 0.007 in men and p = 0.621 in women). Increased serum UA levels might be associated with better outcomes in ischemic stroke patients treated with intravenous thrombolysis, but the effectiveness of UA can differ by initial stroke severity and gender. (C) 2013 S. Karger AG, Basel
引用
收藏
页码:132 / 139
页数:8
相关论文
共 50 条
  • [21] CIRCADIAN VARIATION OF THE EFFICACY OF INTRAVENOUS RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR IN PATIENTS WITH ACUTE ISCHEMIC STROKE
    Kim, J.
    Lee, S.
    [J]. SLEEP, 2018, 41 : A23 - A24
  • [22] CIRCADIAN VARIATION OF EFFICACY OF INTRAVENOUS RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR IN PATIENTS WITH ACUTE ISCHEMIC STROKE
    Lee, S.
    Kim, J. H.
    [J]. INTERNATIONAL JOURNAL OF STROKE, 2018, 13 : 116 - 116
  • [23] PREHOSPITAL STROKE MEDICAL ACTIVATION: IMPACT ON TIMES RESPONSE AND OUTCOME IN PATIENTS WITH ISCHEMIC STROKE TREATED WITH INTRAVENOUS RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR. PRELIMINARY DATA
    Bacelar, N.
    Martinez, M.
    Canovas, D.
    Carvajal, A.
    [J]. INTENSIVE CARE MEDICINE, 2009, 35 : 138 - 138
  • [24] Computerized Tomography Perfusion Predictors of Clinical Outcome in Acute Ischemic Stroke Patients Treated with Intravenous Tissue Plasminogen Activator
    Wu, Tzu-Ching
    Sitton, Clark
    Sahota, Preeti
    Sarraj, Amrou
    Harun, Nusrat
    Pandurengan, Renganayaki
    Gonzales, Nicole R.
    Barreto, Andrew D.
    Lopez, George A.
    Grotta, James C.
    Savitz, Sean I.
    [J]. STROKE, 2011, 42 (03) : E165 - E165
  • [25] Serum Uric Acid as a Good Prognostic Marker in Patients Treated with Recombinant Tissue Plasminogen Activator
    Heo, Sung H.
    Kim, Jun-Hyun
    Chang, Dea-Il
    Lee, Seung-Hoon
    Bu, Seon H.
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2010, 30 (11) : E300 - E300
  • [26] Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with apixaban
    De Smedt, Ann
    Cambron, Melissa
    Nieboer, Koenraad
    Moens, Maarten
    Van Hooff, Robbert-Jan
    Yperzeele, Laetitia
    Jochmans, Kristin
    De Keyser, Jacques
    Brouns, Raf
    [J]. INTERNATIONAL JOURNAL OF STROKE, 2014, 9 (07) : E31 - E31
  • [27] Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator in a Stroke Patient Treated with Dabigatran
    De Smedt, Ann
    De Raedt, Sylvie
    Nieboer, Koenraad
    De Keyser, Jacques
    Brouns, Raf
    [J]. CEREBROVASCULAR DISEASES, 2010, 30 (05) : 533 - 534
  • [28] Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator in a Stroke Patient Treated with Rivaroxaban
    Ishihara, Hideyuki
    Torii, Hiroaki
    Imoto, Hirochika
    Oka, Fumiaki
    Sadahiro, Hirokazu
    Suzuki, Michiyasu
    [J]. JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2014, 23 (10): : E457 - E459
  • [29] Clinical implication of hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator
    Bo-Lin Ho
    Chien-Fu Chen
    Ruey-Tay Lin
    Ching-Kuan Liu
    A-Ching Chao
    [J]. Neurological Sciences, 2016, 37 : 1799 - 1805
  • [30] Clinical implication of hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator
    Ho, Bo-Lin
    Chen, Chien-Fu
    Lin, Ruey-Tay
    Liu, Ching-Kuan
    Chao, A-Ching
    [J]. NEUROLOGICAL SCIENCES, 2016, 37 (11) : 1799 - 1805